Literature DB >> 7880117

Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis.

R M Hembry1, M R Bagga, J J Reynolds, D L Hamblen.   

Abstract

OBJECTIVE: To assess the likely importance of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the arthritic process.
METHODS: Synovial samples from seven joints with rheumatoid arthritis and three osteoarthritic joints were analysed by indirect immunofluorescence microscopy. Using specific human antisera, we documented the frequencies and distributions of collagenase, stromelysins 1 and 2, matrilysin, gelatinases A and B, TIMP-1, and TIMP-2.
RESULTS: Stromelysin 1 was found in all synovia, bound to extracellular matrix, within cells, or both, indicating stromelysin synthesis. Matrilysin was present in only one active inflammatory synovium, and focal synthesis of collagenase and gelatinase A was seen in four synovia. Stromelysin 2 and TIMP-2 were not observed, but TIMP-1 synthesis was seen in five synovia, and in two active synovia the distribution of TIMP-1 positive cells was more widespread than that of MMPs.
CONCLUSIONS: The presence of stromelysin 1 in all synovia clearly implicates this enzyme in joint damage. Collagenase, gelatinase A and matrilysin may also have a role in rheumatoid arthritis, but are not significant in osteoarthritis. However, marked regional variations were found in the synthesis of these MMPs, indicating not only that these diseases are episodic but that control of enzyme synthesis is focal. Only TIMP-1 may be considered an inhibitory factor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7880117      PMCID: PMC1005508          DOI: 10.1136/ard.54.1.25

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  31 in total

1.  The role of the C-terminal domain in collagenase and stromelysin specificity.

Authors:  G Murphy; J A Allan; F Willenbrock; M I Cockett; J P O'Connell; A J Docherty
Journal:  J Biol Chem       Date:  1992-05-15       Impact factor: 5.157

2.  Purification and characterization of human 72-kDa gelatinase (type IV collagenase). Use of immunolocalisation to demonstrate the non-coordinate regulation of the 72-kDa and 95-kDa gelatinases by human fibroblasts.

Authors:  D S Hipps; R M Hembry; A J Docherty; J J Reynolds; G Murphy
Journal:  Biol Chem Hoppe Seyler       Date:  1991-04

Review 3.  Mechanisms of matrix degradation in rheumatoid arthritis.

Authors:  S M Krane; W Conca; M L Stephenson; E P Amento; M B Goldring
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

4.  In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium.

Authors:  E M Gravallese; J M Darling; A L Ladd; J N Katz; L H Glimcher
Journal:  Arthritis Rheum       Date:  1991-09

5.  The matrix metalloprotease matrilysin (PUMP) is expressed in developing human mononuclear phagocytes.

Authors:  D F Busiek; F P Ross; S McDonnell; G Murphy; L M Matrisian; H G Welgus
Journal:  J Biol Chem       Date:  1992-05-05       Impact factor: 5.157

6.  Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury.

Authors:  L A Walakovits; V L Moore; N Bhardwaj; G S Gallick; M W Lark
Journal:  Arthritis Rheum       Date:  1992-01

7.  Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant.

Authors:  G Murphy; Q Nguyen; M I Cockett; S J Atkinson; J A Allan; C G Knight; F Willenbrock; A J Docherty
Journal:  J Biol Chem       Date:  1994-03-04       Impact factor: 5.157

8.  Immunohistochemical demonstration of collagenase and tissue inhibitor of metalloproteinases (TIMP) in synovial lining cells of rheumatoid synovium.

Authors:  Y Okada; Y Gonoji; I Nakanishi; H Nagase; T Hayakawa
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1990

9.  The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases.

Authors:  G Murphy; F Willenbrock; R V Ward; M I Cockett; D Eaton; A J Docherty
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

10.  Binding of latent and high Mr active forms of stromelysin to collagen is mediated by the C-terminal domain.

Authors:  J A Allan; R M Hembry; S Angal; J J Reynolds; G Murphy
Journal:  J Cell Sci       Date:  1991-08       Impact factor: 5.285

View more
  38 in total

1.  Distribution of matrix metalloproteinases and their inhibitor, TIMP-1, in developing human osteophytic bone.

Authors:  S Bord; A Horner; R M Hembry; J J Reynolds; J E Compston
Journal:  J Anat       Date:  1997-07       Impact factor: 2.610

2.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis.

Authors:  Y Yoshihara; H Nakamura; K Obata; H Yamada; T Hayakawa; K Fujikawa; Y Okada
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

3.  Excessıve fluorıde ıntake alters the MMP-2, TIMP-1 and TGF-β levels of perıodontal soft tıssues: an experımental study ın rabbıts.

Authors:  Müge Lütfioğlu; Elif Eser Sakallıoğlu; Umur Sakallıoğlu; M Yavuz Gülbahar; Mehtap Muğlalı; Burcu Baş; Abdurrahman Aksoy
Journal:  Clin Oral Investig       Date:  2011-12-07       Impact factor: 3.573

4.  Apparent tradeoff of higher activity in MMP-12 for enhanced stability and flexibility in MMP-3.

Authors:  Xiangyang Liang; A Arunima; Yingchu Zhao; Rajagopalan Bhaskaran; Anuradha Shende; Todd S Byrne; Jeremy Fleeks; Mark O Palmier; Steven R Van Doren
Journal:  Biophys J       Date:  2010-07-07       Impact factor: 4.033

5.  Up-regulation of the inflammatory response by ovariectomy in collagen-induced arthritis. effects of tin protoporphyrin IX.

Authors:  Lidia Ibáñez; Maria José Alcaraz; Nuria Maicas; David Guede; José Ramón Caeiro; Marije I Koenders; Wim B van den Berg; Maria Luisa Ferrándiz
Journal:  Inflammation       Date:  2011-12       Impact factor: 4.092

6.  TNF-alpha-mediated expression of membrane-type matrix metalloproteinase in rheumatoid synovial fibroblasts.

Authors:  K Migita; K Eguchi; Y Kawabe; Y Ichinose; T Tsukada; T Aoyagi; H Nakamura; S Nagataki
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

7.  Overexpression of matrix metalloproteinase-10 and matrix metalloproteinase-3 in human diabetic corneas: a possible mechanism of basement membrane and integrin alterations.

Authors:  M Saghizadeh; D J Brown; R Castellon; M Chwa; G H Huang; J Y Ljubimova; S Rosenberg; K S Spirin; R B Stolitenko; W Adachi; S Kinoshita; G Murphy; L J Windsor; M C Kenney; A V Ljubimov
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

Review 8.  Clinical potential of matrix metalloprotease inhibitors in cancer therapy.

Authors:  E I Heath; L B Grochow
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

9.  Increased matrix metalloproteinases as possible cause of osseoarticular tissue destruction in long-term haemodialysis and beta 2-microglobulin amyloidosis.

Authors:  K Ohashi; R Kawai; M Hara; Y Okada; S Tachibana; Y Ogura
Journal:  Virchows Arch       Date:  1996-04       Impact factor: 4.064

Review 10.  Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor.

Authors:  Jean-Michel Dayer; Ernest Choy
Journal:  Rheumatology (Oxford)       Date:  2009-10-23       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.